Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talimogene Laherparepvec in Non-Muscle Invasive Bladder Cancer
NCT03430687Phase 1Withdrawn
- Sponsor
- University of California, San Francisco
- Start
- Jun 2018
- Primary completion
- Dec 2019
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of talimogene laherparepvec in Non-muscle-invasive bladder cancer (NMIBC), sponsored by University of California, San Francisco. Primary endpoints: Incidence of treatment-related toxicities up to 2 years, Pathologic T0 rate at 6 months and 1 more. Planned start Jun 2018; status: withdrawn.
02
Drugs
talimogene laherparepvec
03
Conditions
Non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT03430687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03430687.